Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis

Current Medical Research and Opinion
Clare McCormickRichard O'Callaghan

Abstract

To quantitatively determine, in a Pseudomonas keratitis model, the anti-inflammatory and bactericidal properties of a new formulation of tobramycin (0.3%) and dexamethasone (0.05%) that utilizes a xanthan gum vehicle. In a randomized and masked fashion, rabbit corneas (n>/=16 eyes per group) were intrastromally injected with 10(3) colony-forming units (CFU) of P. aeruginosa. Eyes were untreated or were administered a single drop every 15 min between 16 and 17 h postinfection (PI) and then a single drop every 30 min between 17 and 22 h PI, a total of 15 drops of either 0.1% dexamethasone and 0.3% tobramycin (TobraDex; Tdex) or a new formulation 0.3% tobramycin and 0.05% dexamethasone with xanthan gum (TobraDex ST; ST). Slit lamp examination scores (SLE+/-SEM) were derived from grading seven parameters at 22 h PI. Rabbits were sacrificed at 23 h PI and the log CFU+/-SEM per cornea was determined. Untreated eyes had SLE scores of 11.11+/-0.43 and had log CFU of 7.27+/-0.06. Eyes treated with Tdex, as compared to the untreated eyes, had significantly lower SLE scores (7.39+/-0.21, p<0.0001) and significantly fewer bacteria (6.32+/-0.29 log CFU, p=0.0213). Eyes treated with ST had a SLE score (6.56+/-0.19) that was significantly low...Continue Reading

References

Sep 1, 1978·American Journal of Ophthalmology·H M LeibowitzR L Kimbrough
Jul 1, 1980·Archives of Ophthalmology·H M Leibowitz, A Kupferman
Jan 1, 1996·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·G MeseguerR Gurny
Feb 1, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Charles N J McGheeHelen Danesh-Meyer
Aug 9, 2002·DNA and Cell Biology·Joseph J DajcsRichard J O'Callaghan
Sep 22, 2007·The Journal of Pharmacy and Pharmacology·C Umamaheswara ReddyB S R Reddy
Oct 13, 2007·European Journal of Ophthalmology·F I CamesascaUNKNOWN Italian Betamethasone-Chloramphenicol vs Dexamethasone-Tobramycin Combination Study Group
Oct 27, 2007·Investigative Ophthalmology & Visual Science·Richard J O'CallaghanJonathan D Fratkin

❮ Previous
Next ❯

Citations

Nov 4, 2010·Advances in Therapy·Charles L BalzliRichard J O'Callaghan
Jan 29, 2011·Journal of Biomedicine & Biotechnology·Mary E Marquart
Jul 14, 2012·Clinical Ophthalmology·Mark Dp Willcox
Jun 19, 2012·Expert Opinion on Drug Delivery·Priyanka PahujaPravin Pawar
Dec 25, 2010·Veterinary Ophthalmology·Alan L Weiner, Brian C Gilger
Aug 6, 2013·The Journal of Infection·Kang ChenXi Huang
Nov 8, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Joshua Seth EatonChristopher J Murphy
Jul 22, 2017·International Journal of Molecular Medicine·Litao GuoXiaobo Tan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.